Determination of candidate genes involved in schizophrenia using the whole-exome sequencing

Senormanci O. | Karatas Celik S. | Valipour E. | Dogan V. | Senormanci G.

Article | 2018 | Bratislava Medical Journal119 ( 9 ) , pp.572 - 576

OBJECTIVES: We used the whole-exome sequencing to evaluate several genes suspected of being involved in the pathogenesis of schizophrenia. METHODS: The study sample was composed of two families. In the first family, two siblings had schizophrenia, and the parents were healthy. In the second family, two siblings had schizophrenia, while the other sibling and the parents did not. RESULTS: Indels were detected in some genes, including SPON1, GRIA3, SMAD5, PCLO, KMT2C, SRD5A2, SEMA3B, NCOR2, GPHB5, FAM174B, CLTCL1, and TMEM216. The insertion of three nucleotides (TGA) was detected in the sequence of the PCLO gene. The mutation resulted . . .in the insertion of aspartic acid (Asp, D) in the amino acid sequence of the PCLO protein. Indels detected in SPON1, GRIA3, SMAD5, KMT2C, SRD5A2, SEMA3B, GPHB5, CLTCL1, and TMEM216 were shown to be frameshifting. Bioinformatics analysis showed that the indels in SPON1, GRIA3, SMAD5, KMT2C, SRD5A2, SEMA3B, NCOR2, GPHB5, FAM174B, CLTCL1, and TMEM216 had a damaging effect, while the indel in PCLO had a non-damaging effect on protein function. CONCLUSION: To the best of our knowledge, no previous studies have examined the relationship between the pathogenesis of schizophrenia and the gene mutations identified in this study. © 2018, Comenius University Daha fazlası Daha az

Total white blood cell count, liver enzymes, and metabolic syndrome in schizophrenia

Karakaş Uğurlu G. | Ulusoy Kaymak S. | Uğurlu M. | Örsel S. | Çayköylü A.

Article | 2016 | Turkish Journal of Medical Sciences46 ( 2 ) , pp.259 - 264

Background/aim: Metabolic syndrome (MetS) is an important clinical issue in patients with schizophrenia, but its associated factors are still ambiguous. The aim of the present study was to test whether there are any associations between MetS and white blood cell (WBC) levels, liver enzymes, or sociodemographic variables. Materials and methods: The study included 91 patients with a diagnosis of schizophrenia. We used the National Cholesterol Education Program’s Third Adult Treatment Protocol criteria to evaluate MetS in patients. Schizophrenia patients with MetS were compared with those without MetS on the basis of demographic and cl . . .inical characteristics and total WBC counts. We conducted Spearman’s correlation and binary logistic regression analyses to achieve the best prediction of MetS in schizophrenia. Results: Compared with schizophrenia patients without MetS, those with MetS were older, less educated, and more likely to be smokers. They were also more likely to have a longer duration of the illness, a longer untreated period, and higher alanine aminotransferase (ALT) and WBC levels. MetS was correlated with age, duration of illness, income, ALT, gamma-glutamyl transpeptidase, WBC, and hemoglobin values. Age and WBC levels were found to be the best predictors of MetS. Conclusion: Hemograms and liver tests should be conducted to test for MetS in schizophrenia. © TÜBİTAK Daha fazlası Daha az

Substance use effects on the characteristics of crime and violence in schizophrenia [Şizofreni hastalarında madde kullanımının suç ve şiddet özelliklerine etkisi]

Çİnİk E. | Güçlü O. | Şenormanci Ö. | Aydin E. | Erkiran M. | Erkmen H.

Article | 2015 | Anadolu Psikiyatri Dergisi16 ( 2 ) , pp.104 - 112

Objective: The aim of our study is to examine the effects of the substance abuse on criminal and violent behaviors, clinical features of the disease in criminal male with schizophrenia.Methods: Male inpatients with schizophrenia diagnosed according to the DSM-IV criteria who had been hospitalized for observation or mandatory treatment in Bakırköy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery forensic psychiatry unit were participated in the study. Patients with substance use disorders according to the DSM-IV criteria at any time of their life and/or at that time were assessed, two groups as patients with . . .(n=50) and without comorbidity were evaluated using the questionnaire for demographic and clinical characteristics, Positive and Negative Syndrome Scale (PANNS), Schedule for Assessing the Three Components of Insight and Taylor’s Violence Rating Scale.Results: In our study 90% of schizophrenia patients with substance abuse comorbidity were paranoid subtype. In case of comorbidity, number of committed crimes were higher, involved serious violence included homicide and attempted homicide using frequently knives and fire guns. Eighty-eight percent of the patients with substance abuse comorbidity stated that they used cannabinoid and several substances during these crimes. Their PANSS scores were higher. It had been found that they had experienced more physical violence at childhood, more suicidal attempts and self-injury behaviors.Conclusions: Substance abuse co-morbidity in schizophrenia markedly affects the psychopathology, violent behaviors, criminal behaviors and compliance with the treatment. Studies investigating the causal relationship between substance and crime in schizophrenia can be helpful in the development of methods targeting protection. © 2015, Cukurova University, Faculty of Medicine. All rights reserved Daha fazlası Daha az

Nitric oxide as a physiopathological factor in neuropsychiatric disorders

Akyol O. | Zoroglu S. | Armutcu F. | Sahin S. | Gurel A.

Review | 2004 | In Vivo18 ( 3 ) , pp.377 - 390

The dominant research subject on schizophrenia, mood disorders, autism and other central nervous system diseases has been related to neurotransmitter system abnormalities. For example, the dopamine hypothesis states that schizophrenia is the result of dopaminergic hyperactivity. The therapeutic approach has also been directed towards finding agents which will modulate or regulate these neurotransmitter systems at any step. There is substantial and mounting evidence that subtle abnormalities of reactive oxygen species (ROS) and nitric oxide (NO) may underlie a wide range of neuropsychiatric disorders. NO has chemical properties that . . .make it uniquely suitable as an intracellular and intercellular messenger. It is produced by the activity of nitric oxide synthases which are present in peripheral tissues and in neurons. On the other hand, NO is known to be an oxygen radical in the central and peripheral nervous systems. NO has been implicated in a number of physiological functions such as noradrenaline and dopamine releases, memory and learning and certain pathologies such as schizophrenia, bipolar disorder and major depression. Evidence has been considered here for the proposal that an abnormality of NO metabolism may be a contributory factor in some neuropsychiatric disorders. The direct evidence for NO abnormalities in schizophrenia and other psychiatric disorders remains relatively limited to date, although there are some clinical and experimental studies. The suggestion that NO and other ROS may play a role in some neuropsychiatric disorders clearly has important implications for new treatment possibilities. The primary objective of the present review was to summarize and critically evaluate the current knowledge regarding a potential contribution of NO to the neuropathophysiology of schizophrenia as well as other neuropsychiatric disorders Daha fazlası Daha az

Pain perception in patients with bipolar disorder and schizophrenia

Atik L. | Konuk N. | Akay O. | Ozturk D. | Erdogan A.

Article | 2007 | Acta Neuropsychiatrica19 ( 5 ) , pp.284 - 290

Objective: Pain perception is reported to be altered in patients with depression and schizophrenia. However, few studies have investigated the pain perception in patients with bipolar disorders. We therefore aimed to compare pain sensitivity between patients with bipolar disorder, schizophrenia and controls. Methods: Study groups consisted of 30 patients with bipolar disorder, and control groups consisted of 27 patients with schizophrenia and 59 healthy subjects. Pain perception was assessed with cold pressor test (CPT) by exposure to ice-water. Results: Patients with schizophrenia had significantly higher pain thresholds (PTh) than . . . patients with bipolar disorder. There were no differences between the PTh of patients with schizophrenia and healthy control subjects. However, patients with bipolar disorder had significantly lower pain tolerance (PT) in the CPT than patients with schizophrenia and corresponding healthy control subjects. Conclusions: The higher PTh in the schizophrenia group compared with the bipolar group found in this study supports further investigation of a potential difference in the pain perception between patients with schizophrenia and bipolar disorder. Theoretical implications of these findings and possible relevant behavioural and neurochemical mechanisms are discussed. © 2007 Blackwell Munksgaard Daha fazlası Daha az

6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.